More than 96 Percent of People Have Antibodies After One Vaccine
UMMATIMES - Recent research reveals more than 96 percent of people develop coronavirus antibodies after receiving only one dose of AstraZeneca or Pfizer vaccines. The study by University College London (UCL) scientists followed more than 8,000 participants.
The study found that nearly 100 percent of people developed immune cells to successfully fight the coronavirus after two doses of the vaccine. The study itself is based in England and Wales.
The researchers found that 96.42 percent of people who received the AstraZeneca or Pfizer vaccines developed antibodies 28 to 34 days after the first dose. That number grew to 99.08 percent within seven to 14 days of receiving the second injection.
"This is one of the earliest world vaccine studies in the UK and this is incredible news," said lead author of the study paper Maddie Shrotri.
Shrotri said nearly all adults in the UK who receive the Pfizer or AstraZeneca vaccines produce antibodies against the virus within one month of their first injection. "How well this vaccine works is incredible, especially given the speed at which it is developed. This is a real scientific achievement in the face of the most devastating pandemic in a century," said Shrotri.
UCL scientists have also found that Pfizer or AstraZeneca are both capable of triggering an antibody response that can ward off severe coronavirus infections. However, antibody levels after one injection were found to be lower in the elderly and those with underlying health conditions. Among them are cancer, diabetes and heart disease. The differences were then resolved after the participants received a second dose of vaccine.
"This study is a timely reminder of the importance of receiving a second dose. But it also reassures the vaccine is our way out of the pandemic," said UCL study lead researcher Prof. Rob Aldridge.
The study by the UCL scientists could have positive implications for the world war against the coronavirus pandemic. However, these studies will be placed through a peer review process before submitting them to medical journals.